sponsored
PatientsVille.com Logo

PatientsVille

Rivaroxaban Medical Research Studies

Up-to-date List of Rivaroxaban Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Rivaroxaban Medical Research Studies

Rank Status Study
1 Recruiting Dose-finding of Rivaroxaban in Hemodialysis
Condition: Chronic Renal Failure
Intervention: Drug: Rivaroxaban 10 mg
Outcome Measures: Pharmacokinetics and pharmacodynamics of Rivaroxaban in hemodialysis patients;   Dialytic removal of Rivaroxaban;   Safety and tolerability of Rivaroxaban in hemodialysis patients
2 Recruiting Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Condition: Heparin-induced Thrombocytopenia
Intervention: Drug: Rivaroxaban
Outcome Measures: Incidence of new symptomatic venous and arterial thromboembolism in the study population.;   Incidence of symptomatic venous and arterial thromboembolism and major bleeding in patients while on-treatment with Rivaroxaban.;   Duration of time to platelet recovery in patients with Serotonin Release Assay (SRA) confirmed HIT;   Incidence of venous and arterial thromboembolism in patients with SRA confirmed HIT who receive Rivaroxaban.;   Major bleeding in the entire study population and in patients with SRA confirmed HIT who receive Rivaroxaban.;   To collect data to prospectively validate a new clinical prediction rule for HIT
3 Not yet recruiting A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Conditions: Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions: Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
Outcome Measures: Time from randomization to the first occurrence of symptomatic venous thromboembolism event (VTE) and VTE-related death;   Time from randomization to the first occurrence of major bleeding;   Time from randomization to an occurrence of VTE-related death;   Time from randomization to the first occurrence of a symptomatic VTE;   Time from randomization to the first occurrence of a composite of symptomatic VTE and all-cause mortality (ACM);   Time from randomization to an occurrence of ACM
4 Recruiting Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Condition: Prevention & Control
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Outcome Measures: Time from randomization to the first occurrence of either myocardial infarction, stroke, or cardiovascular death;   Time from randomization to the first occurrence of major bleeding (modified International Society on Thrombosis and Haemostasis);   Time from randomization to first occurrence of either myocardial infarction, stroke, cardiovascular death, venous thromboembolism or cardiovascular hospitalization;   Time from randomization to first occurrence of all-cause mortality
5 Not yet recruiting Rivaroxaban for Antiphospholipid Antibody Syndrome
Condition: Antiphospholipid Antibody Syndrome
Intervention: Drug: Rivaroxaban
Outcome Measures: Feasibility of identification for enrolment;   Feasibility of Consent;   Compliance;   Bleeding;   Thrombosis
6 Not yet recruiting Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
Conditions: Ischemic Stroke;   TIA
Interventions: Drug: Rivaroxaban;   Drug: Aspirin;   Drug: placebo
Outcome Measures: percentage of patients with new stroke (ischemic or hemorrhage);   Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death);   mRS score changes (continuous) and dichotomized at percentage with score 0 to 2 versus 3 to 6;   Changes in NIHSS scores;   moderate to severe bleeding events;   Total mortality;   Adverse events/severe adverse events reported by the investigators
7 Recruiting Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Conditions: Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention: Drug: Rivaroxaban
Outcome Measures: recurrent symptomatic deep venous thrombosis, pulmonary embolism or both;   incidentally detected VTE;   Major or clinically relevant non-major bleedings;   recurrent VTE according to the risk of clinical prediction rule
8 Not yet recruiting Rivaroxaban in Thrombotic Antiphospholipid Syndrome
Condition: Antiphospholipid Syndrome
Intervention: Drug: Experimental: Rivaroxaban
Outcome Measures: Cumulative outcome measure will be incident acute thrombosis (arterial or venous) confirmed by appropriate imaging studies, major bleeding, or death.;   • Any single type of thromboembolic event;   All-cause mortality
9 Recruiting Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Conditions: Ischemic Stroke;   Transient Ischemic Attack
Interventions: Drug: Rivaroxaban;   Drug: Warfarin
Outcome Measures: Composite of MRI-defined intracranial bleeding and recurrent ischemic lesion;   The number of patients with Intracranial bleeding;   The number of patients with recurrent ischemic lesion;   Length of hospitalization;   modified Rankin Score
10 Recruiting Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
Conditions: Atrial Fibrillation or Pulmonary Embolism;   Need of Long Term Oral Anticoagulation Therapy (OAT);   Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
Intervention: Drug: Rivaroxaban or Marcumar
Outcome Measures: Progression of coronary and aortic valve calcification (Agatston Score);   Serum chemistry including Matrix Gla Protein (MPG) level changes and Fetuin-A (baseline/ follow up);   Changes in intima-media thickness of carotid artery (IMT) and flow-mediated vasodilation of brachial artery (FMD);   Progression of aortic calcification (aortic Agatston Score);   Changes in ventricular diastolic function parameters as determined by echocardiography (strain/strain-rate imaging)
11 Recruiting A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Conditions: Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions: Drug: Rivaroxaban 2.5 mg;   Drug: Rivaroxaban 15 mg;   Drug: Rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Outcome Measures: Number of participants with clinically significant bleeding;   Number of participants with clinically significant bleeding events;   Number of participants with the adverse cardiovascular events (cardiovascular death, Myocardial Infarction, stroke, stent thrombosis);   Number of participants with adverse events;   Event composite of clinically significant bleeding and adverse cardiovascular events
12 Recruiting Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
Conditions: Atrial Fibrillation;   Stroke;   Thrombo-embolism;   Bleeding
Interventions: Drug: Rivaroxaban;   Drug: Warfarin and Enoxaparin
Outcome Measures: Thrombosis;   Mortality;   Hospitalizations;   Bleeding
13 Not yet recruiting Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
Condition: Gastric Bypass Status
Intervention: Drug: Rivaroxaban
Outcome Measures: median inhibition of factor xa inhibition;   median prolongation of prothrombin time
14 Recruiting Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
Condition: Atrial Fibrillation
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Outcome Measures: The percentage of subjects with complete resolution of left atrial or left atrial appendage thrombus at the end of treatment;   Categories of thrombus outcome in subjects: resolved, reduced, unchanged, enlarged or new;   The composite number of stroke and non-central nervous system systemic embolism events;   The number of all bleeding events
15 Recruiting Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)
Condition: Pulmonary Embolism
Interventions: Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Outcome Measures: Major bleedings: Intracranial haemorrhage, Gastrointestinal bleeding and Urogenital bleeding;   Drug utilization pattern;   Non-infective liver disease;   Effectiveness outcomes: Deep vein thrombosis and Pulmonary embolism, Ischaemic stroke, Myocardial infarction, Death
16 Recruiting Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
Condition: Pulmonary Embolism
Interventions: Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Outcome Measures: Major bleedings: Intracranial haemorrhage, Gastrointestinal bleeding and Urogenital bleeding;   Drug utilization pattern;   Non-infective liver disease;   Effectiveness outcomes: Deep vein thrombosis and Pulmonary embolism, Ischaemic stroke, Myocardial infarction, Death
17 Recruiting Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
Condition: Brain Ischemia
Intervention: Drug: Rivaroxaban (Xarelto_ BAY59-7939)
Outcome Measures: Improvement of treatment satisfaction (Evaluated through ACTS and TSQM questionnaires);   Incidence of ADRs and serious AEs (especially for hemorrhagic events, and liver disfunction with increase of liver-function-relating enzymes including bilirubin);   Incidence of events of stroke;   Incidence of events of non-central nervous system embolism;   Determination of patient's demography which might affect the QOL, safety and efficacy of Xarelto using ACTS and TSQM questionnaires;   Determination of patient's medical history which might affect the QOL, safety and efficacy of Xarelto using ACTS and TSQM questionnaires;   Determination of patient's background which might affect the QOL, safety and efficacy of Xarelto using ACTS and TSQM questionnaires
18 Recruiting A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following Hospitalization for Heart Failure
Conditions: Heart Failure;   Coronary Artery Disease
Interventions: Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Outcome Measures: Time to the first occurrence of any of the following: death from any cause, myocardial infarction, or stroke;   Time to the first occurrence of either fatal bleeding or bleeding into a critical space with potential for permanent disability;   Time to the first occurrence of either death due to a cardiovascular cause or re-hospitalization for worsening of heart failure;   Time to death due to a cardiovascular cause;   Time to rehospitalization for worsening of heart failure;   Time to rehospitalization for cardiovascular events;   Time to bleeding requiring hospitalization
19 Recruiting Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
Condition: Venous Thrombosis
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Outcome Measures: Change of the Anti Clot Treatment Scale (ACTS) score at 3 months compared with baseline score;   Change of ACTS score after 1 and 6 months of treatment;   Continuation rate at 1, 3 and 6 months;   Change of SF36 score at 1, 3 and 6 months (health related quality of life determined by SF36 questionnaire);   Physician's satisfaction at 1, 3 and 6 months assessed by a 5-point Likert scale response ("very satisfied", "satisfied", "neutral", "unsatisfied" or "very unsatisfied");   Patient's compliance with VKA treatment at baseline and with Xarelto treatment at 1, 3 and 6 months assessed by the investigator as good (≥80%), average (50-80%) or poor (<50%)
20 Recruiting Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
Condition: Atrial Fibrillation
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Outcome Measures: Change of the Anti Clot Treatment Scale (ACTS) score at 3 months compared with baseline score;   Change of ACTS score after 1 and 6 months of treatment;   Continuation rate at 1, 3 and 6 months;   Change of SF36 score at 1, 3 and 6 months (health related quality of life determined by SF36 questionnaire);   Physician's satisfaction at 1, 3 and 6 months assessed by a 5-point Likert scale response ("very satisfied", "satisfied", "neutral", "unsatisfied" or "very unsatisfied");   Patient's compliance with VKA treatment at baseline and with Xarelto treatment at 1, 3 and 6 months assessed by the investigator as good (≥80%), average (50-80%) or poor (<50%)

These studies may lead to new treatments and are adding insight into Rivaroxaban etiology and treatment.

A major focus of Rivaroxaban research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Rivaroxaban